Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
about
Granzyme B; the chalk-mark of a cytotoxic lymphocytePeptide Vaccine Therapy in Colorectal CancerThe small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activityMonkeypox virus infection of rhesus macaques induces massive expansion of natural killer cells but suppresses natural killer cell functions.Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myelomaCurcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines.Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials.IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibodyIdentification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
P2860
Q24794483-17E213EE-4ABE-42E9-9371-C53309200EE8Q26830336-63E79775-61AE-4F82-9944-05B4C9D0E3BFQ33986439-44650D1A-2106-4751-BB8B-56083D5F26FCQ35023413-43FD4757-A88F-488C-91DF-FC7244FF2174Q35832185-698AB1F1-D985-444B-AF7B-E26001F44714Q36425427-2EBB9B7D-5E9F-42EA-9D85-9C3CAA01A1E1Q37356349-4F1DAD46-6AED-41D6-A4C6-EE6DC7E32B03Q37372822-013984D7-0199-4830-9D14-1D1EB8E1F30FQ37512173-21E06096-2390-497F-A664-DCF299042D1FQ39451947-286C356A-54F2-41BC-AB9F-DB893F22D1ADQ39705098-90BBAF4D-AEF7-47AB-886F-121D41753D5CQ40439479-58AFAD89-2258-4943-AA03-FC1F3D088C56Q42794690-D214FDA4-0CC0-4268-947B-217154170BB5
P2860
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
description
2004 nî lūn-bûn
@nan
2004 թուականին հրատարակուած գիտական յօդուած
@hyw
2004 թվականին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@ast
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@en
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@nl
type
label
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@ast
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@en
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@nl
prefLabel
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@ast
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@en
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@nl
P2093
P2860
P356
P1476
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
@en
P2093
Anatoli Malyguine
Douglas B Kuhns
Kimberly A Shafer-Weaver
Mark W Burkett
Michael Baseler
Susan L Strobl
Thomas Sayers
P2860
P2888
P356
10.1186/1479-5876-2-31
P577
2004-01-01T00:00:00Z
P5875
P6179
1036018735